Pharmaxis' cystic fibrosis therapy positive at Phase III, pooled data show
This article was originally published in Scrip
Executive Summary
Pharmaxis has released further detailed Phase III clinical results for Bronchitol, which showed clear benefits for the inhaled dry powder formulation of mannitol in cystic fibrosis patients receiving current standard of care.